phase readout

NCT05798156: Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOP

ACTIVE_NOT_RECRUITINGupdated 7h ago

community read0 votes

Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest. Phase: PHASE2. Conditions: Lymphoma, Large B-Cell, Diffuse

Data sources

last refreshed 56m ago

Found something off?

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?